Glibenclamide nanosuspension inhaler: development, in vitro and in vivo assessment

Objective: The development of nanosuspension for targeted delivery of glibenclamide as hypoglycemic agent to the lung in an inhaler dosage form. Method: Glibenclamide nanosuspension formulations were prepared using Box-Behnken design to investigate the effect of independent factors on the dependent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug development and industrial pharmacy 2020-05, Vol.46 (5), p.762-774
Hauptverfasser:	Hashem, Fahima M., Abd Allah, Fathy I., Abdel-Rashid, Rania S., Hassan, Abdelsabour A. A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Blood Glucose - drug effects Blood Glucose - metabolism Diabetes mellitus Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - metabolism Drug Development - methods glibenclamide Glyburide - administration & dosage Glyburide - chemistry Glyburide - metabolism Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - chemistry Hypoglycemic Agents - metabolism inhaler Male Nanoparticles - administration & dosage Nanoparticles - chemistry Nanoparticles - metabolism nanosuspension Nanotechnology - methods Nebulizers and Vaporizers optimization Particle Size Rats
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!